The pharmaceutical firm is following a $35m investment in Gamida Cell last year with up to $15m of cash over the next two years.
Pharmaceutical company Novartis agreed yesterday to invest $15m in Israel-based cellular and immune therapy developer Gamida Cell over the next two years.
Gamida Cell, which is developing treatments for cancer and orphan genetic diseases, will use the cash to advance clinical programmes including NiCord, an experimental treatment for patients with high risk haematological malignancies that Gamida hopes to advance to Phase 3 trials by the middle of 2016.
Novartis, which paid $35m for a 15% stake in Gamida in…
